• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

IBUPROFEN Drug Record

  • Summary
  • Interactions
  • Claims
  • IBUPROFEN chembl:CHEMBL521 Approved

    Alternate Names:

    U-18573
    NOVAPRIN
    FEMAFEN
    IBUMETIN
    PHENSIC
    NUROFEN SOLB
    PACIFENE
    FEVERFEN
    PROFEN
    IBUSPRAY
    PEDEA
    PROFLEX
    TAB-PROFEN
    MEDIPREN
    CHILDREN'S ADVIL-FLAVORED
    APSIFEN-F
    NUROFEN RECOVERY
    PAXOFEN
    RELCOFEN
    FENBID FTE
    IBUDERM
    IB-100
    ORBIFEN
    NUROFEN 400
    CHILDREN'S ADVIL
    ANADIN LIQUIFAST
    FENPAED
    INOVEN
    LOBUFEN
    NUROFEN BACK PAIN SR
    EBUFAC
    ANADIN ULTRA
    ADVIL MIGRAINE LIQUI-GELS
    IBU-TAB 200
    CAP-PROFEN
    PEDIATRIC ADVIL
    IBULEVE
    DEEP RELIEF
    ANADIN JOINT PAIN
    JUNIOR STRENGTH IBUPROFEN
    PHORPAIN MAX STRGH
    MIDOL LIQUID GELS
    CHILDREN'S IBUPROFEN
    JUNIOR STRENGTH ADVIL
    IBUCALM
    ADVIL LIQUI-GELS
    FENBID
    NUROFEN SINUS
    RIMAFEN
    FLEXIMEX
    IBUMED
    IBUGEL
    SUSPREN
    PHORPAIN
    MOTRIN
    NSC-256857
    IBUTIME
    PROFLEX SR
    IBUFAC
    NUROFEN PLUS
    CUPROFEN PLUS
    ARTHROFEN 400
    IBUGEL FTE
    LIDIFEN-F
    ADVIL
    JUNIOR STRENGTH MOTRIN
    IBUPRIN
    ANADIN PERIOD PAIN RELIEF
    CALDOLOR
    INABRIN
    MIGRAFEN
    IBU-TAB
    IP-82
    APSIFEN
    CHILDREN'S MOTRIN
    LIDIFEN
    MOTRIN IB
    M01AE01
    MAXA-GESIC
    IBU-SLO
    ACHES-N-PAIN
    BRUFEN RET
    MIDOL
    CHILDREN'S ELIXSURE
    SECLODIN
    CO-OP
    ARTHROFEN 600
    CUPROFEN FOR CHILD
    IBUPROHM
    NUROFEN CHILD
    IBUPROFEN
    PHOR PAIN
    ISISFEN
    IBUMOUSSE
    RD 13621
    MANORFEN
    NUPRIN
    MANDAFEN
    RUFEN
    CODAFEN CONTINUS
    MOTRIN MIGRAINE PAIN
    ARTHROFEN 200
    NUROFEN FOR CHILD
    IBULAR
    JUNIFEN
    ADVIL®
    P-ISOBUTYL-2-PHENYLPROPIONATE
    (±)-2-(P-ISOBUTYLPHENYL)PROPIONIC ACID
    (+-)-2-(P-ISOBUTYLPHENYL)PROPIONIC ACID
    ALPHA-(4-ISOBUTYLPHENYL)PROPIONATE
    P-ISOBUTYLHYDRATROPIC ACID
    ALPHA-(4-ISOBUTYLPHENYL)PROPIONIC ACID
    IBUPROPHEN
    DURALBUPROFEN
    ALPHA-P-ISOBUTYLPHENYLPROPIONATE
    MOTRIN®
    (+-)-IBUPROFEN
    NUROFEN®
    P-ISOBUTYLHYDRATROPATE
    Α-(4-ISOBUTYLPHENYL)PROPIONIC ACID
    Α-(P-ISOBUTYLPHENYL)PROPIONIC ACID
    ALPHA-P-ISOBUTYLPHENYLPROPIONIC ACID
    2-(4-ISOBUTYLPHENYL)PROPANOIC ACID
    BRUFEN®
    (±)-IBUPROFEN
    ALPHA-(P-ISOBUTYLPHENYL)PROPIONIC ACID
    P-ISOBUTYL-2-PHENYLPROPIONIC ACID
    (+-)-ALPHA-METHYL-4-(2-METHYLPROPYL)BENZENEACETIC ACID
    (4-ISOBUTYLPHENYL)-Α-METHYLACETIC ACID
    (+-)-P-ISOBUTYLHYDRATROPIC ACID
    (±)-Α-METHYL-4-(2-METHYLPROPYL)BENZENEACETIC ACID
    (4-ISOBUTYLPHENYL)-ALPHA-METHYLACETIC ACID
    4-ISOBUTYLHYDRATROPIC ACID
    (RS)-IBUPROFEN
    (±)-P-ISOBUTYLHYDRATROPIC ACID
    rxcui:5640
    chemidplus:15687-27-1
    drugbank:01050
    chembl:CHEMBL521
    pubchem.compound:3672

    Drug Info:

    Drug Class anti-inflammatory agents, non-steroidal
    Year of Approval 1984
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications NSAID
    (6 More Sources)

    Publications:

    Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
    Grosser T, 2009, Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy., J Investig Med
    Lee YS et al., 2006, Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs., Clin Pharmacol Ther
    Ouellet et al., 2004, Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms., Biochem. J.
    Gallego-Sandín et al., 2004, Effect of ibuprofen on cyclooxygenase and nitric oxide synthase of gastric mucosa: correlation with endoscopic lesions and adverse reactions., Dig. Dis. Sci.
    Sánchez-Fidalgo et al., 2004, Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor., Eur. J. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Chavez et al., 2003, Valdecoxib: a review., Clin Ther
    Murphey et al., 2004, Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer., Anal. Biochem.
    Vitale P et al., 2013, Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors., J Med Chem
    Gupta et al., 2004, Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors., Bioorg. Med. Chem. Lett.
    Yu et al., 2013, Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro., Biopharm Drug Dispos
    Martić et al., 2004, Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors., Eur J Med Chem
    Patrignani, 2003, Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease., Thromb. Res.
    Hillarp, 2004, [Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism]., Lakartidningen
    Buchanan et al., 2007, Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer., Cancer Res.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Vrtic et al., 2003, Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug., Br J Clin Pharmacol
    Abran et al., 1997, Characterization and regulation of prostaglandin E2 receptor and receptor-coupled functions in the choroidal vasculature of the pig during development., Circ. Res.
    Chemtob et al., 1996, Regulation of cerebrovascular prostaglandin E2 (PGE2) and PGF2 alpha receptors and their functions during development., Semin. Perinatol.
    Quidville et al., 2006, 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line., Prostaglandins Other Lipid Mediat.
    Jakubíková et al., 2001, Non-steroidal anti-inflammatory agent ibuprofen-induced apoptosis, cell necrosis and cell cycle alterations in human leukemic cells in vitro., Neoplasma
    Hockertz et al., 1996, Treatment of an acute bacterial infection with a combination of acetylsalicylic acid/ibuprofen and interferon gamma., Arzneimittelforschung
    Palayoor et al., 2004, Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function., Clin. Cancer Res.
    Zajic SC et al., 2019, Individuals with CYP2C8 and CYP2C9 reduced metabolism haplotypes self-adjusted ibuprofen dose in the Coriell Personalized Medicine Collaborative., Pharmacogenet Genomics
    Ochoa D et al., 2015, Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers., Pharmacogenomics
    García-Martín E et al., 2004, Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms., Clin Pharmacol Ther
    Karaźniewicz-Łada M et al., 2009, Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes., Xenobiotica
    López-Rodríguez R et al., 2008, Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers., Pharmacol Res
    Blanco G et al., 2008, Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding., Pharmacogenet Genomics
    Brueggemeier et al., 2005, Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer., J. Steroid Biochem. Mol. Biol.
    Tsutsumi et al., 2004, Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis., Cell Death Differ.
    Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med
  • IBUPROFEN   AMACR

    Interaction Score: 3.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • IBUPROFEN   UGT2B17

    Interaction Score: 3.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • IBUPROFEN   UGT2B4

    Interaction Score: 3.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • IBUPROFEN   PTGER4

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9118476


    Sources:
    NCI

  • IBUPROFEN   PTGER1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9118476 8870119


    Sources:
    NCI

  • IBUPROFEN   CYP2C8

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30562214 26122864 25502615 15289789 19480553 18694831 18216720


    Sources:
    PharmGKB

  • IBUPROFEN   PTGS1

    Interaction Score: 0.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name HZT-501, ibuprofen + famotidine,Duexa
    Novel drug target Established target
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    23651359 14741265 23536207 14987823 11752352 12852704 14592549 15575422 25502615


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • IBUPROFEN   CXCR1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • IBUPROFEN   PTGS2

    Interaction Score: 0.33

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name HZT-501, ibuprofen + famotidine,Duexa
    Novel drug target Established target
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    25502615 19602986 16678543 14510637 15481334 15556152 11752352 12852704 15494133


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • IBUPROFEN   UGT1A3

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • IBUPROFEN   VHL

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15217953


    Sources:
    NCI

  • IBUPROFEN   IFNG

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8931897


    Sources:
    NCI

  • IBUPROFEN   UGT1A9

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • IBUPROFEN   APC

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft
    Response Type sensitive

    PMIDs:
    17909047


    Sources:
    JAX-CKB

  • IBUPROFEN   UGT2B7

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • IBUPROFEN   FAAH

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • IBUPROFEN   NOS2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • IBUPROFEN   NOS3

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • IBUPROFEN   CXCR2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • IBUPROFEN   DDIT3

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15131590


    Sources:
    NCI

  • IBUPROFEN   CYP19A1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15964185


    Sources:
    NCI

  • IBUPROFEN   NOS1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • IBUPROFEN   CXCL8

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • IBUPROFEN   PIK3CA

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30683736


    Sources:
    CIViC

  • IBUPROFEN   TARDBP

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • IBUPROFEN   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615 22931300


    Sources:
    DTC PharmGKB

  • IBUPROFEN   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11583291


    Sources:
    NCI

  • IBUPROFEN   HPGD

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16997128


    Sources:
    NCI

  • IBUPROFEN   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300 12580991


    Sources:
    DTC NCI

  • IBUPROFEN   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • IBUPROFEN   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615 22931300


    Sources:
    DTC PharmGKB

  • IBUPROFEN   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TEND: IBUPROFEN

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Year of Approval 1984
    Drug Class anti-inflammatory agents, non-steroidal

    Publications:

  • TdgClinicalTrial: IBUPROFEN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications NSAID
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: IBUPROFEN

    • Version: 14-September-2017

    Alternate Names:
    C561 NCI drug code

    Drug Info:

    Publications:
    Chemtob et al., 1996, Regulation of cerebrovascular prostaglandin E2 (PGE2) and PGF2 alpha receptors and their functions during development., Semin. Perinatol.
    Abran et al., 1997, Characterization and regulation of prostaglandin E2 receptor and receptor-coupled functions in the choroidal vasculature of the pig during development., Circ. Res.
    Jakubíková et al., 2001, Non-steroidal anti-inflammatory agent ibuprofen-induced apoptosis, cell necrosis and cell cycle alterations in human leukemic cells in vitro., Neoplasma

  • DTC: IBUPROFEN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL521 ChEMBL Drug ID

    Drug Info:

    Publications:
    Vitale P et al., 2013, Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors., J Med Chem
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • JAX-CKB: Ibuprofen

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Buchanan et al., 2007, Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer., Cancer Res.

  • PharmGKB: ibuprofen

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
    Lee YS et al., 2006, Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs., Clin Pharmacol Ther
    Grosser T, 2009, Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy., J Investig Med

  • CIViC: IBUPROFEN

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med

  • TTD: Ibuprofen

    • Version: 2020.06.01

    Alternate Names:
    D0R1QE TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL521

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL521

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21